Pharmacogenetic Data Will Have “Safe Harbor,” CDER’s Galson Says

FDA is encouraging companies to submit pharmacogenetic data to the agency under the assurance that data suggesting risk of a product will not impact regulatory decisions, Center for Drug Evaluation & Research Deputy Director Steve Galson, MD, said May 16